Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,873 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diagnosis of Melanoma Clear all
Completed Phase 1 Interventional

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

NCT00405405
View directory record Official record
Conditions
Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma, Stage IV Head and Neck Cancer
Interventions
Cisplatin, Docetaxel, Bevacizumab, Erlotinib, Radiotherapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 27, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain

NCT00550654
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy, image-guided radiation therapy, tomotherapy
Other · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma

NCT00665470
View directory record Official record
Conditions
Skin Cancer, Metastatic Melanoma
Interventions
Aldesleukin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma

NCT00223899
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
VCL-IM01 (encoding IL-2) with Electroporation
Genetic
Lead sponsor
Vical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Mobile, Alabama • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 27, 2026, 5:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma

NCT01435499
View directory record Official record
Conditions
Melanoma
Interventions
melanoma GVAX, Cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 27, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

NCT04768881
View directory record Official record
Conditions
Locally Advanced Unresectable or Metastatic Melanoma
Interventions
Selinexor, Pembrolizumab
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Pasadena, California • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 27, 2026, 5:48 PM EDT
Completed No phase listed Observational

Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo

NCT00574392
View directory record Official record
Conditions
Basal Cell Carcinoma, Melanoma, Non-Malignant Skin Disorders, Squamous Cell Carcinoma
Interventions
Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 27, 2026, 5:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

NCT02743611
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
Interventions
BPX-701, Rimiducid
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Denver, Colorado • Portland, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 27, 2026, 5:48 PM EDT
Withdrawn Phase 2 Interventional

SBRT as a Vaccination for Metastatic Melanoma

NCT04042506
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 27, 2026, 5:48 PM EDT
Active, not recruiting Phase 1 Interventional

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

NCT04616248
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma
Interventions
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy, Recombinant Flt3 Ligand, Pembrolizumab, Tocilizumab
Biological · Drug · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes

NCT02416336
View directory record Official record
Conditions
Melanoma, Head and Neck Cancer, Breast Cancer
Interventions
Sentinella Intraoperative imaging protocol
Device
Lead sponsor
Oncovision Inc
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity

NCT00001577
View directory record Official record
Conditions
Melanoma, Sarcoma
Interventions
double isolated limb perfusion with melphalan alone
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Treatment for Advanced Malignant Melanoma

NCT00300612
View directory record Official record
Conditions
Malignant Melanoma
Interventions
HyperAcute-Melanoma Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 27, 2026, 5:48 PM EDT
Recruiting No phase listed Observational

DESTINY-PANTUMOUR04

NCT07124000
View directory record Official record
Conditions
Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 27, 2026, 5:48 PM EDT
Terminated Phase 2 Interventional Results available

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

NCT01551693
View directory record Official record
Conditions
Melanoma
Interventions
STA-9090
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 27, 2026, 5:48 PM EDT
Recruiting Phase 2 Interventional

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

NCT04594187
View directory record Official record
Conditions
Melanoma
Interventions
Immunotherapy, Quality-of-Life Assessment, Radiation Therapy
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Jacksonville, Florida • Camden, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Trial of pIL-12 Electroporation Malignant Melanoma

NCT01502293
View directory record Official record
Conditions
Melanoma
Interventions
Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

NCT00527657
View directory record Official record
Conditions
Brain Neoplasms, Melanoma
Interventions
Lomustine, Temozolomide, Thalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 27, 2026, 5:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

NCT01217411
View directory record Official record
Conditions
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 27, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

NCT01585194
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 27, 2026, 5:48 PM EDT
Not listed Phase 1 Interventional

Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma

NCT00002781
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
boronophenylalanine-fructose complex
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 27, 2026, 5:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NCT03901573
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Interventions
NT-I7, atezolizumab
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 27, 2026, 5:48 PM EDT